SEC EDGARAUG 201 min read$ARWR

OLUKOTUN ADEOYE Y sold $174K of ARWR

OLUKOTUN ADEOYE Y sold 2,000 shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $86.96 ($0.17M total) on 2026-08-18.

Original reporting

SEC EDGAR · OLUKOTUN ADEOYE Y

Published Aug 20, 2026, 9:25 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 20, 2026, 9:27 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$ARWR

Neutral

high confidence

Mentioned

$ARWR

Relevance

4/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ARWRNeutralLow

Why it matters

The disclosed sale is modest and does not suggest a shift in company fundamentals. Investors may note the reduction in insider ownership but should not expect a price move.

Market read

Routine insider sale with limited trading relevance; primarily of interest to shareholders tracking insider activity.

What to watch

Potential upcoming corporate actions or clinical trial outcomes not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: filing date 2026-08-20

Background

SEC Form 4 filings disclose insider transactions. Directors often sell shares for personal reasons; such sales are routinely monitored by investors.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ARWRNeutralHigh confidence

Context

Director Olukotun Adeoye Y sold 2,000 shares for $173,920 on 2026-08-18, reducing holdings to 31,600 shares.

Expected impact

Minimal short-term price effect; likely absorbed by market without noticeable move.

Evidence & confidence

The transaction size (~$174K) is small relative to market cap and typical trading volume, and no accompanying corporate event is disclosed.

Market effects

Sector

None; the sale does not affect the broader biotech/pharma sector.

Regional

None; limited to Arrowhead Pharmaceuticals shareholders.

Global

None; no macro or global implications.

Counterpoint

What could challenge this read

The sale could be a signal of insider concern if followed by additional disposals.

Key entities

Company
Arrowhead Pharmaceuticals, Inc.
Biopharmaceutical company developing RNAi therapeutics (NASDAQ: ARWR).
Individual
Olukotun Adeoye Y
Director of Arrowhead Pharmaceuticals who sold shares.

Read at source ← All news

SEP 4

$ARWRHighAI 9/10

Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?

Arrowhead Pharmaceuticals (ARWR) reported Phase 3 trial results for plozasiran, showing 79-81% triglyceride reductions vs. 27% for placebo. Pooled analysis indicated a 78% reduction in pancreatitis events, but absolute risk reduction was 4.1%. ARWR plans to submit a broader-label application by 2026. Plozasiran is FDA-approved for familial chylomicronemia syndrome. The company aims to expand its use to severe hypertriglyceridemia. Triglyceride reductions were consistent, with 91-93% of treated p

insidermonkey.com2 min

AUG 31

$ARWRMedAI 8/10

Plozasiran durably cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia

Plozasiran, an FDA-approved drug by Arrowhead, reduced triglycerides by up to 81% in severe hypertriglyceridemia patients and prevented pancreatitis. Two trials, SHASTA-3 and SHASTA-4, showed sustained reductions and favorable safety profiles. Gerald F. Watts, a cardiometabolic medicine professor, highlighted the therapy's potential impact on clinical practice. The drug is not yet approved for severe hypertriglyceridemia.

healio.com2 min

AUG 31

$ARWRHighAI 8/10

Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split

Arrowhead Pharmaceuticals presented late-stage trial results for plozasiran (Redemplo) in severe hypertriglyceridemia, showing favorable safety and efficacy. Analysts are divided: Stifel highlights its safety and dosing advantages over Ionis' Tryngolza, while BMO favors Tryngolza due to glycemic control concerns. Arrowhead plans an FDA submission for expanded use later this year.

biospace.com3 min

AUG 30

$ARWRHighAI 8/10

Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglycer

Arrowhead Pharmaceuticals presented Phase 3 data showing plozasiran reduced triglycerides by 79-81% and acute pancreatitis events by 78% in severe hypertriglyceridemia patients. Over 90% of patients achieved TG levels below 500 mg/dL. The company plans to file an FDA application by year-end 2026, utilizing a Priority Review Voucher. Plozasiran demonstrated a favorable safety profile.

finanznachrichten.de2 min

AUG 17

$ARWRMedAI 8/10

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.

ir.arrowheadpharma.com4 min

AUG 11

$ARWRMed

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Arrowhead Pharmaceuticals (ARWR) reported Q3 2026 results. Sales rose to $75.25 million from $27.77 million a year earlier, but net loss widened to $194.28 million and loss per share increased to $1.36 from $1.26. For the first nine months of 2026, it swung to a $296.21 million net loss despite $400+ million in sales, citing higher expenses and lower collaboration revenue.

simplywall.st6 min